Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Ordinary Shares, Nominal value 0.12 per share
-
Shares outstanding
-
112M
-
Number of holders
-
90
-
Total 13F shares, excl. options
-
72M
-
Shares change
-
-140K
-
Total reported value, excl. options
-
$1.38B
-
Value change
-
-$7.86M
-
Put/Call ratio
-
3.56
-
Number of buys
-
54
-
Number of sells
-
-27
-
Price
-
$19.21
Significant Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) as of Q2 2024
102 filings reported holding NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share as of Q2 2024.
NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) has 90 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72M shares
of 112M outstanding shares and own 64.15% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (12.2M shares), FCPM III SERVICES B.V. (11.8M shares), Bain Capital Life Sciences Investors, LLC (10.5M shares), RA CAPITAL MANAGEMENT, L.P. (8.06M shares), VIKING GLOBAL INVESTORS LP (8.02M shares), Medicxi Ventures Management (Jersey) Ltd (2.87M shares), Cormorant Asset Management, LP (2.3M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.53M shares), BVF INC/IL (1.52M shares), and MILLENNIUM MANAGEMENT LLC (1.17M shares).
This table shows the top 90 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.